Pre HIV Injections: How the 2‑Month Shot Works

Long-acting HIV prevention injections are designed for people who want protection that does not depend on taking a tablet every day. The most widely discussed option is injectable PrEP, which uses an antiretroviral medicine called cabotegravir to help prevent HIV before exposure happens. Rather than replacing safer sex practices or regular medical care, this approach adds another prevention tool. For many people, its main appeal is consistency: after the start-up phase, injections are generally scheduled every two months and are given by a healthcare professional.

This article is for informational purposes only and should not be considered medical advice. Please consult a qualified healthcare professional for personalized guidance and treatment.

What injectable PrEP is and how it works

Injectable PrEP is a form of pre-exposure prophylaxis, meaning it is used by people who do not have HIV but may benefit from prevention support. The long-acting medicine most commonly used for this purpose is cabotegravir. After it is injected into a muscle, the drug is released slowly over time, helping maintain protective levels in the body between visits. This is different from oral PrEP, which relies on regular pill-taking. The injection does not treat existing HIV infection, so confirming HIV-negative status before starting and during follow-up is a central part of safe use.

Who may be eligible: assessing risk and suitability

Eligibility depends on local approval rules, age requirements, medical history, and an individual’s level of HIV exposure risk. In general, injectable PrEP may be considered for adults and some adolescents who are HIV-negative and who could benefit from reliable prevention. That can include people who have vaginal or anal sex in situations where HIV exposure is possible, people with partners whose HIV status is unknown, or people who find daily oral medication hard to maintain. It may also be useful for those who prefer less frequent dosing or who want a private routine that is managed through clinic visits.

Suitability is not only about risk. A clinician will usually review recent HIV testing, any symptoms that could suggest very early HIV infection, prior use of PrEP or post-exposure prophylaxis, pregnancy considerations, and current medicines. Injectable PrEP may not be appropriate if someone may already have HIV or cannot attend regular follow-up appointments, since timely testing and repeat injections are important for safety and effectiveness.

How injections are given and the recommended dosing schedule

The injection is typically given into the gluteal muscle by a trained healthcare professional. The schedule usually starts with an initial injection, followed by a second injection one month later. After that, the maintenance schedule is generally every two months. In some settings, an oral lead-in with cabotegravir may be offered to check tolerability before the first injection, but this is not always required. The exact process can vary by country, clinic protocol, and the product approved in that region.

Regular HIV testing is a key part of the schedule, not an optional extra. Testing is usually done before starting and before each injection visit to reduce the risk of giving the medicine to someone with undiagnosed HIV infection. Some clinics may also discuss STI screening, pregnancy-related considerations, and broader sexual health care during follow-up. Because the medicine remains in the body for a long time after stopping, people who discontinue injections but still have HIV exposure risk may need another prevention plan.

Side effects, safety monitoring, and potential interactions

The most common side effects are injection-site reactions such as pain, tenderness, swelling, or firmness where the shot was given. These reactions are often mild to moderate and tend to improve over time, though some people find them bothersome. Other possible effects can include headache, fever, tiredness, muscle aches, nausea, or dizziness. Serious reactions are less common, but any severe or unexpected symptom should be reviewed by a clinician.

Safety monitoring focuses heavily on HIV testing because starting or continuing injectable PrEP during undiagnosed HIV infection can increase the chance of drug resistance. A clinician may also review liver health, past allergic reactions, and general medical history. Potential drug interactions are fewer than with many other medicines, but they still matter. Certain medications that strongly affect drug metabolism, including some seizure medicines and some tuberculosis treatments such as rifampin or rifapentine, may lower cabotegravir levels and reduce protection. Sharing a full medication list, including supplements and over-the-counter products, is important.

What happens if a dose is missed or stopped

Missing a scheduled injection can reduce protection, especially if the gap becomes longer than recommended. Clinics usually have guidance for how to restart or bridge treatment, which may include rescheduling promptly or using an oral prevention option for a period of time. The right approach depends on how late the dose is and whether HIV exposure may have occurred.

Stopping injectable PrEP also deserves planning. Cabotegravir can stay in the body at low levels for many months after the last dose. During that period, if a person is still at risk of HIV exposure, a clinician may suggest switching to another PrEP method rather than simply ending care. This “tail period” is one reason follow-up matters even after injections stop.

For people considering this option, the main questions are practical as much as medical: whether regular clinic visits fit their life, whether they prefer a long-acting method over a daily pill, and whether their current medicines or health history affect suitability. Injectable PrEP can be a useful prevention approach when it is matched to a person’s needs, monitored carefully, and used as part of broader sexual health care.